Klaus Hollmig Selected Research

Pharmaceutical Preparations

10/2008

Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Klaus Hollmig Research Topics

Disease

9	Multiple Myeloma 08/2009 - 03/2006
4	Chromosome Aberrations (Chromosome Abnormalities) 10/2008 - 04/2006
3	Disease Progression 10/2008 - 03/2006
1	Smoldering Multiple Myeloma 10/2008
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2008
1	Plasmacytoma 02/2007
1	Monoclonal Gammopathy of Undetermined Significance 02/2007
1	Paraproteinemias (Monoclonal Gammopathy) 09/2006
1	Peripheral Nervous System Diseases (PNS Diseases) 03/2006
1	Venous Thrombosis (Deep-Vein Thrombosis) 03/2006

Drug/Important Bio-Agent (IBA)

4	Thalidomide (Thalomid)FDA Link 10/2008 - 03/2006
2	Melphalan (Alkeran)FDA LinkGeneric 01/2008 - 03/2006
1	Pharmaceutical PreparationsIBA 10/2008
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 07/2007
1	Bortezomib (Velcade)FDA Link 07/2007
1	CreatinineIBA 07/2007
1	Biomarkers (Surrogate Marker)IBA 02/2007
1	Messenger RNA (mRNA)IBA 09/2006

Therapy/Procedure

9	Therapeutics 08/2009 - 03/2006
3	Transplantation 08/2007 - 04/2006
2	Drug Therapy (Chemotherapy) 01/2008 - 03/2006
2	Autologous Transplantation 01/2008 - 08/2007
1	Salvage Therapy 10/2008
1	Hematopoietic Stem Cell Mobilization 01/2008
1	Stem Cell Transplantation 09/2006
1	Combination Drug Therapy (Combination Chemotherapy) 04/2006
1	Hematopoietic Stem Cell Transplantation 03/2006
1	Cell Transplantation 03/2006